4D Molecular Therapeutics (FDMT) Cash & Equivalents (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Cash & Equivalents of $72.5 million for Q1 2026, down 45.71% year-over-year from $133.5 million in Q1 2025, and up 20.33% quarter-over-quarter from $60.2 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Cash & Equivalents (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Cash & Equivalents for 8 consecutive years, with $72.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 45.71% year-over-year to $72.5 million; the TTM figure through Mar 2026 stood at $72.5 million (down 45.71% YoY), while the FY2025 annual figure was $60.2 million, down 59.66% from the prior year.
- Cash & Equivalents rose to $72.5 million in Q1 2026 per FDMT's latest filing, from $60.2 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $275.7 million in Q3 2023 and bottomed at $48.6 million in Q3 2025.
- Historically, Cash & Equivalents has averaged $140.2 million across 5 years, with a median of $113.5 million in 2022.
- Annual changes were most pronounced in 2023 — Cash & Equivalents surged 375.84% — and 2025, when it slumped 74.11%.
- 4D Molecular Therapeutics' Cash & Equivalents stood at $52.4 million in 2022, then jumped by 375.84% to $249.1 million in 2023, then slumped by 40.05% to $149.3 million in 2024, then sank by 59.66% to $60.2 million in 2025, then increased by 20.33% to $72.5 million in 2026.
- Business Quant data shows FDMT's Cash & Equivalents at $72.5 million in Q1 2026, $60.2 million in Q4 2025, and $48.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 70.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.37 Mn |
| Mar 31, 2026 | 72.49 Mn |
| Dec 31, 2025 | 60.24 Mn |
| Sep 30, 2025 | 48.56 Mn |
| Jun 30, 2025 | 77.16 Mn |
| Mar 31, 2025 | 133.53 Mn |
| Dec 31, 2024 | 149.34 Mn |
| Sep 30, 2024 | 187.54 Mn |
| Jun 30, 2024 | 189.06 Mn |
| Mar 31, 2024 | 275.59 Mn |
| Dec 31, 2023 | 249.11 Mn |
| Sep 30, 2023 | 275.68 Mn |
| Jun 30, 2023 | 236.31 Mn |
| Mar 31, 2023 | 78.57 Mn |
| Dec 31, 2022 | 52.35 Mn |
| Sep 30, 2022 | 108.30 Mn |
| Jun 30, 2022 | 113.48 Mn |
| Mar 31, 2022 | 75.97 Mn |
| Dec 31, 2021 | 153.00 Mn |
| Sep 30, 2021 | 90.99 Mn |